• Slowed tumor progression and growth, blocked HIF-1α activation, and impaired glycolysis (Mathupala et al., 2004; Murray et al., 2005; Sonveaux et al., 2008; Mendoza-Juez et al., 2012; Sonveaux et al., 2012; Beloueche-Babari et al., 2017)• Decreased lactate efflux and induction of cell death (Mathupala et al., 2004)• Can sensitize cells to biguanides (Granja et al., 2014; Marchiq et al., 2015). The gene discussed is HIF1A; the disease is neoplasm.